Showing posts with label Illumina. Show all posts
Showing posts with label Illumina. Show all posts

Tuesday 18 December 2018

Biochip Market Expected To Trigger A Revenue Increase To USD 25.84 Billion By 2024:Key Participant Abbott Laboratories, PerkinElmer, Inc.


San Francisco, 18 December 2018, Biochip Market Analysis By Type, (DNA Chips, Lab-On-a-Chip, Protein Chips, Cancer Diagnosis And Treatment, Gene Expression, Single Nucleotide Polymorphism (SNP) Genotyping, Genomics, Drug Discovery, Agricultural Biotechnology, Proteomics, Expression Profiling, High Throughput Screening), By End Use (Biotechnology & Pharmaceutical Companies, Hospitals & Diagnostics Centers, Academic & Research Institutes), And Segment Forecasts To 2024

Global biochip market to reach USD 25.84 billion by 2024, according to a new report by Grand View Research, Inc. Growing adoption of personalized medicine and rapid technological advancements in the biochips market along with high market demand from proteomic and genomic applications is expected to drive market growth. 
Anticipated launch and commercialization of novel products for diagnosis and treatment including laboratory- and non-laboratory-based research are expected to further reinforce growth in demand. Improvements in accuracy, resolution, and preparation procedures for the technology coupled with reduction in costs of associated materials are expected to fuel growth over the forecast period. 
Ongoing developments related to further miniaturization of biochips are expected to enhance their applicability and additional usage for genetic sequencing methodologies, such as cancer genomics. Their usage is also expected to aid reduction in the cost of genome profiling, which is a factor likely to drive demand for the next step of genetic analysis, i.e., protein expression analysis. Consequently, a growth in the number of such protein profiling studies is expected to directly fuel demand for genomic and proteomic labeling techniques through to 2024. 
Access Full Research Report On Biochip Market  Analysis: www.grandviewresearch.com/industry-analysis/biochips-market

Further Key Findings From the Report Suggest:
·         DNA chips form the largest revenue-generating segment of the biochip applications. Major contribution to this share comes from usage in cancer diagnostics/treatment and drug discovery applications. DNA chips accounted for around a third of the global market revenue in 2015. The other notable contributing segments to application of biochips include gene expression, single nucleotide polymorphism genotyping, genomic studies, and agricultural biotechnology.
·         The market is expected to have a high potential for growth as the technology has numerous applications to aid the miniaturization of molecular biology and biochemical & chemical assays. Over time, such miniaturization is expected to benefit medical technologies in terms of cost and input requirements.
·         DNA chips, lab-on-a-chip, protein chips, and tissue & cell arrays find a number of uses in pharmaceutical & biotechnology companies, academic & research institutes, hospitals & diagnostic centers, and other end users like point-of-care settings, forensic labs, blood banks, etc.
·         North America was the largest revenue-generating region and accounted for over 45%of total revenue in 2015. This can be attributed to by the presence of government initiatives for personalized patient care coupled with the availability of a very large installed base of genetic and proteomic profiling platforms across the U.S. High market usage of next-gen sequencing techniques for molecular diagnosis and treatment used with microfluidic techniques also add to the large share. Furthermore, cancer analysis projects in a number of academic and clinical research institutes are also responsible for the region’s large share.
·         Some key players operating in this industry include Abbott Laboratories; PerkinElmer, Inc.; GE Healthcare; Illumina, Inc.; Thermo Fisher Scientific, Inc.; Merck Millipore; Agilent Technologies, Inc.; Sigma-Aldrich Corporation; Fluidigm Corporation; and Bio-Rad Laboratories, Inc. 
Browse More Reports Of This Category By Grand View Research At:  www.grandviewresearch.com/industry/biotechnology
Grand View Research has segmented the Biochip market on the basis of type, end use, region:
Biochip Outlook, by Type (Revenue, USD Million, 2013 - 2024)
·         DNA chips, by application
o    Cancer diagnosis and treatment
o    Gene expression
o    Single Nucleotide Polymorphisms Genotyping
o    Genomics.
o    Drug discovery
o    Agricultural biotechnology
o     Others
·         Lab-on-a-chip, by application
o    Genomics
o    IVD & POC
o    Proteomics
o    Drug discovery
o     Others
·         Protein chips, by application
o    Proteomics
o    Expression Profiling
o    Diagnostics
o    HTS
o    Drug Discovery
o    Others
·         Tissue Arrays
·         Cell Arrays
Biochip Outlook, by End Use (Revenue, USD Million, 2013 - 2024)
·         Biotechnology and Pharmaceutical Companies
·         Hospitals and Diagnostics Centers
·         Academic & Research Institutes
·         Others
Biochip Regional Outlook (Revenue, USD Million, 2013 - 2024)
·         North America
o    U.S.
o    Canada
·         Europe
o    Germany
o     UK
·         Asia Pacific
o    China
o    Japan
·         Latin America
o     Brazil
·         MEA
o    South Africa

Access Full Press Release of this Report:
www.grandviewresearch.com/press-release/global-biochip-market

About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com/



Predictive Genetic Testing & Consumer/Wellness Genomics Market Expected To Trigger A Revenue Increase To USD 4.6 Billion By 2025:Key Participant Genesis Genetics, 23andMe, Inc


The global predictivegenetic testing & consumer/wellness genomics market is anticipated to reach USD 4.6 billion by 2025, according to a new report by Grand View Research, Inc. Key drivers attributing to the market expansion include rising awareness pertaining to the use of genomic tests for the prediction of gene susceptibility for probability of disease development. Genetic data in the ecosystem increases when consumers buy direct-to-consumer genomics products or participate in clinical research trials.
Rising encouragement for the use of these products is anticipated to propel industrial growth. Expansion in the range of consumer genetic tests by market entities is anticipated to fuel progress in the market in the coming years. Introduction of novel platforms anticipates the DNA-powered applications thus rising market penetration.
Moreover, the pharmaceutical companies are also engaged in partnerships with genomics companies in order to develop novel therapeutics on the basis of genotypic and phenotypic correlations. For instance, in April 2016 a ten-year deal was signed between Human Longevity Inc. (HLI) and AstraZeneca, in which HLI is supposed to sequence 500,000 genomes of the clinical trial population of AstraZeneca. This data is to be used for the identification of novel drug targets. The deal also provides AstraZeneca with access to the proprietary knowledgebase in order augment biomarker discovery, and facilitate drug development.
Access Full Research Report On Predictive Genetic Testing & Consumer/Wellness Genomics Market Analysis:
www.grandviewresearch.com/industry-analysis/predictive-genetic-testing-consumer-wellness-genomics-market

Further Key Findings from the Study Suggest:
·         Application of genetic susceptibility tests in gynecology and endocrinology, is of great interest thereby resulting to higher adoption.
·         These tests enable the identification of the susceptibility of genes towards postmenopausal osteoporosis, adenomyosis, and endometriosis.
·         Breast & ovarian cancer based predictive testing accounted for the largest share owing to the rising use of susceptibility testing for BRCA mutations cancer prediction.
·         Government and pertinent organizations are engaged in endeavors aimed at curbing cancer-related healthcare expenditure by encouraging patients to undergo regular diagnostic examinations.
·         CRC screening initiatives undertaken by the governments and implementation of mass CRC screening programs is expected to increase the demand for CRC screening tests.
·         Asia Pacific is anticipated to witness substantial growth in the coming years owing to accelerated uptake of these predictive tests in the developing economies of this region.
·         Key players contributing in this market are BGI, Illumina, Inc, Pathway Genomics, Genesis Genetics, 23andMe, Inc, ARUP Laboratories, Color Genomics Inc., and Myriad Genetics, Inc.
·         These entities are involved in collaborations in order to develop their portfolio with respect to fragmented point-solutions across the genomics value chain.
Browse More Reports Of This Category By Grand View Research At:   www.grandviewresearch.com/industry/clinical-diagnostics
Grand View Research has segmented the predictive genetic testing & consumer/wellness genomics market on the basis of test type, application, and region:
Test Type Outlook (Revenue, USD Million, 2013-2025)
·         Predictive Testing
o    Genetic Susceptibility Test
o    Predictive Diagnostics
o    Population Screening
·         Consumer Genomics
·         Wellness Genomics
Application Outlook (Revenue, USD Million, 2013-2025)
·         Predictive Genetic Testing & Consumer Genomics
o    Breast & Ovarian Cancer
o    Cardiovascular screening
o    Diabetic Screening & Monitoring
o    Colon Cancer
o    Parkinsonism / Alzheimer’s Disease
o    Urologic screening/ Prostate cancer screening
o    Orthopedic & Musculoskeletal
o    Other cancer screening
o    Other diseases
·         Wellness Genomics
o    Nutria Genetics
o    Skin & Metabolism Genetics
o    Others
Regional Outlook (Revenue, USD Million, 2013-2025)
·         North America
o    U.S.
o    Canada
·         Europe
o    Germany
o    UK
·         Asia Pacific
o    Japan
o    China
o    Australia
o    India
o    Singapore
·         Latin America
o    Brazil
·         Middle East and Africa (MEA)
o    South Africa

About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com/